These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3756887)

  • 61. Verapamil reversal of clinical doxorubicin resistance in human cancer. A Wilshire Oncology Medical Group pilot phase I-II study.
    Presant CA; Kennedy PS; Wiseman C; Gala K; Bouzaglou A; Wyres M; Naessig V
    Am J Clin Oncol; 1986 Aug; 9(4):355-7. PubMed ID: 3751973
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Combined recombinant human interferon alpha 2 and cytotoxic agents studied in a clonogenic assay.
    Welander CE; Morgan TM; Homesley HD; Trotta PP; Spiegel RJ
    Int J Cancer; 1985 Jun; 35(6):721-9. PubMed ID: 4008100
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Role of recombinant interferon alpha 2 and cimetidine in patients with advanced malignant melanoma.
    Mughal TI; Robinson WA; Thomas MR; Spiegel R
    J Cancer Res Clin Oncol; 1988; 114(1):108-9. PubMed ID: 3350837
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Intralesional alpha interferon therapy in papillary superficial transitional cell carcinoma of the bladder. A pilot study.
    Di Stasi SM; Virgili G; Vespasiani G; Porena M; Micali F
    Br J Urol; 1993 Apr; 71(4):422-6. PubMed ID: 8499986
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase I study of recombinant human interferon beta in patients with advanced cancer.
    Hu E; Horning SJ
    J Biol Response Mod; 1987 Apr; 6(2):121-9. PubMed ID: 3585409
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Phase I study of recombinant human interferon alpha-2C in patients with chemotherapy-refractory malignancies.
    Janssen JT; Ludwig H; Scheithauer W; de Pauw BE; Keyser A; van Tol R; Flener R
    Oncology; 1985; 42 Suppl 1():3-6. PubMed ID: 4080299
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A phase I study of rDNA alpha-2b interferon as a 6-week continuous intravenous infusion.
    Smith D; Wagstaff J; Thatcher N; Scarffe H
    Cancer Chemother Pharmacol; 1987; 20(4):327-31. PubMed ID: 3690806
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Use of interferon in the treatment of ovarian cancer as a single agent and in combination with cytotoxic drugs.
    Welander CE
    Cancer; 1987 Feb; 59(3 Suppl):617-9. PubMed ID: 3802026
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phase I study on the sequential administration of recombinant human interferon-gamma and recombinant human interleukin-2 in patients with metastatic solid tumors.
    Baars JW; Wagstaff J; Boven E; Vermorken JB; van Groeningen CJ; Scheper RJ; Fonk JC; Nijman HW; Franks CR; Damsma O
    J Natl Cancer Inst; 1991 Oct; 83(19):1408-10. PubMed ID: 1920484
    [No Abstract]   [Full Text] [Related]  

  • 70. A phase I toxicity study of human rDNA interferon in patients with solid tumours.
    Wagstaff J; Chadwick G; Howell A; Thatcher N; Scarffe JH; Crowther D
    Cancer Chemother Pharmacol; 1984; 13(2):100-5. PubMed ID: 6467493
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers.
    Kirkwood JM; Ernstoff MS; Davis CA; Reiss M; Ferraresi R; Rudnick SA
    Ann Intern Med; 1985 Jul; 103(1):32-6. PubMed ID: 4003987
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase I combined modality clinical trial of alpha-2-interferon and radiotherapy.
    Torrisi J; Berg C; Harter K; Lvovsky E; Yeung K; Woolley P; Bonnem E; Dritschilo A
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1453-6. PubMed ID: 3759573
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Lonidamine and human lymphoblastoid alpha interferon in metastatic cancer: a phase I study.
    Weinerman B
    Cancer Invest; 1990; 8(5):505-8. PubMed ID: 2265373
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Management of cancer patients receiving interferon alfa-2a.
    Gauci L
    Int J Cancer Suppl; 1987; 1():21-30. PubMed ID: 3476474
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Toxicities of human recombinant interferon-alpha 2 in patients with advanced prostate carcinoma.
    Chang AY; Fisher HA; Spiers AS; Boros L
    J Interferon Res; 1986 Dec; 6(6):713-5. PubMed ID: 3572090
    [TBL] [Abstract][Full Text] [Related]  

  • 76. In vitro data supporting interferon plus cytotoxic agent combinations.
    Von Hoff DD
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):58-61. PubMed ID: 1948130
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Phase-I trial of UltrapureTM human leukocyte interferon in human malignancy.
    Budd GT; Bukowski RM; Miketo L; Yen-Lieberman B; Proffitt MR
    Cancer Chemother Pharmacol; 1984; 12(1):39-42. PubMed ID: 6690072
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A phase I clinical tolerance study of rDNA alpha 2 human interferon in patients with non-reticuloendothelial system malignancies.
    Edelstein MB; Schellekens H; Laurent T; Gauci L
    Eur J Cancer Clin Oncol; 1983 Jul; 19(7):891-4. PubMed ID: 6350014
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Recombinant interferon in advanced breast cancer.
    Nethersell A; Smedley H; Katrak M; Wheeler T; Sikora K
    Br J Cancer; 1984 May; 49(5):615-20. PubMed ID: 6722009
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Reversible arrhythmias observed in patients treated with recombinant alpha 2 interferon.
    Martino S; Ratanatharathorn V; Karanes C; Samal BA; Sohn YH; Rudnick SA
    J Cancer Res Clin Oncol; 1987; 113(4):376-8. PubMed ID: 3597523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.